Michael Artinger

Neurexis is developing an optimized peptide with demonstrated efficacy and safety in small and large animal models of global cerebral ischemia.

Zebra Analytix was established to develop and commercialize miniature gas chromatography (GC) systems based on microelectromechanical systems (MEMS) technology exclusively licensed from Virginia Tech University. The patents-pending technology offers microfabricated chips capable of multi-channel separations. Advantages include vastly decreased instrument size, versatility, portability, and speed of results.

i-Seq Biotechnology, Inc. was formed in 2024 to advance novel, broad-spectrum, vaccines and therapeutics against infectious disease pathogens impacting human health globally.

Cellia Science brings rapid, accurate blood cell assays out of the lab and into the clinic.

Addressing the significant threat to global health posed by current and future pathogens is a critical unmet need laid bare by the ongoing pandemic. Both traditional and emerging approaches to creating vaccines have limitations, and new options are urgently required. Solaris is applying a technology previously used for inactivating pathogens in the blood supply to rapidly produce safe and effective vaccines against viruses, bacteria and parasites under the trade name SolaVAX™.

Neurexis is developing an optimized peptide with demonstrated efficacy and safety in small and large animal models of global cerebral ischemia.

VIC Tech is a life science venture studio that builds companies around high-impact life science innovations sourced from leading research institutions worldwide. Our process begins with in-depth analysis of life science sub-sectors to uncover white-space opportunities ripe for disruption. We then identify, vet, and license the most promising technologies for commercialization. Once a company is formed, VIC provides hands-on support across executive leadership, scientific and engineering development, accounting, marketing, and more. We guide portfolio companies through key milestones and fundraising efforts, with a typical path to exit via acquisition. VIC operates nationally, with specialized offices focusing on medical devices, diagnostics, and therapeutics. Our portfolio companies are built around technologies exclusively licensed from top global institutions—ranging from breakthrough medical devices to transformative therapeutics addressing critical unmet needs. VIC also manages the VIC Investor Network (VIN), giving members access to thoroughly vetted investment opportunities within our cost-efficient, risk-mitigating ecosystem. Our companies have a strong track record of rapid value creation. Experienced investors benefit from attractive early-stage valuations and high return potential, while new investors can participate with low minimums, gaining exposure to multiple ventures as they build confidence.